Clinical Trial

Imaging Markers of Alzheimer's Disease

Study Description

Phase 1 Evaluation of [18F]MK-6240 PET as an Imaging Marker for Tau Protein

The overall goal of this protocol is to evaluate [18F]MK-6240 (also known as [18F]MNI-946) a tau targeted radiopharmaceutical.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Drug - [18F] MNI-946

Subjects will undergo PET imaging using [18F]MNI-946, a PET radioligand for imaging tau.

Drug - [18F]Florbetapir

Subjects with Alzheimer's disease will receive a [18F]florbetapir scan to compare distribution of tau in the brain compared to that of [18F]MNI-946.

Additional Information

Official Study Title

Phase 1 Evaluation of [18F]MK-6240 PET as an Imaging Marker for Tau Protein in the Brain of Patients With Alzheimer's Disease Compared to Healthy Volunteers

Clinical Trial ID

NCT03071224

ParticipAid ID

Xe07Kd